Also, the pan-PIM kinase inhibitor SGI1776 enhances lenalidomide’s anti-myeloma activity due to more effective degradation of IKZF1 and IKZF3 in MM cell lines as well as xenografts of myeloma tumors [13]. Here, IKZF1 is linked to plasma cell myeloma.